A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide
糖基化 Fc 融合胰高血糖素样肽-1 受体激动剂与度拉糖肽相比，具有同等的降血糖效果，但胃肠道副作用较少
期刊:Diabetes Obesity & Metabolism
影响因子:5.4
doi:10.1111/dom.14058
In Bok An, Mi Sun Byun, Sang In Yang, Yuri Choi, Jung Won Woo, Hak Chul Jang, Young Chul Sung
